<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044420</url>
  </required_header>
  <id_info>
    <org_study_id>FOLFIRI-AEC2</org_study_id>
    <nct_id>NCT01044420</nct_id>
  </id_info>
  <brief_title>mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some&#xD;
      showed that irinotecan may be effective. The investigators previous study has shown the&#xD;
      efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study,&#xD;
      the investigators would like to observe the efficacy and safety of Irinotecan/5FU/leucovorin&#xD;
      as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>after each cycle of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>mFOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRI</intervention_name>
    <description>mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks</description>
    <arm_group_label>mFOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age 18 to 70 years old&#xD;
&#xD;
          -  Histologically confirmed esophageal squamous carcinoma,failed to 1st line treatment of&#xD;
             paclitaxel/cisplatin&#xD;
&#xD;
          -  Unresectable recurrent or metastatic disease&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria(diameter of the lesion should be&#xD;
             more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image&#xD;
             should be less than 15 days before enrollment)&#xD;
&#xD;
          -  Karnofsky performance status ≥70&#xD;
&#xD;
          -  Life expectancy of ≥3 month&#xD;
&#xD;
          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than&#xD;
             4 weeks&#xD;
&#xD;
          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)(within 7&#xD;
             days before enrollment)&#xD;
&#xD;
          -  Serum AKP &lt; 2.5 times ULN (within 7 days before enrollment)&#xD;
&#xD;
          -  Serum creatinine &lt;1.0 times ULN (within 7 days before enrollment)&#xD;
&#xD;
          -  Bilirubin level &lt; 1.0 times ULN (within 7 days before enrollment)&#xD;
&#xD;
          -  WBC&gt;4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3,&#xD;
             Hb&gt;9g/dl(within 7 days before enrollment)&#xD;
&#xD;
          -  No sever complication, such as active gastrointestinal bleeding, perforation,&#xD;
             jaundice, obstruction, non-cancerous fever&gt;38℃；&#xD;
&#xD;
          -  Good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 1 Previous systemic therapy for metastatic esophageal squamous carcinoma&#xD;
&#xD;
          -  Known hypersensitivity to irinotecan&#xD;
&#xD;
          -  Only with Brain or bone metastasis&#xD;
&#xD;
          -  Tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung&#xD;
             metastasis covers more than 25% of lung&#xD;
&#xD;
          -  No measurable lesions, eg. pleural fluid and ascites&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry&#xD;
&#xD;
          -  Heart failure or other sever organ dysfunction, eg. coronary artery disease,&#xD;
             myocardial infarction within the last 6 months or&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Other previous malignancy within 5 year, except non-melanoma skin cancer&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Mentally abnormal or disable cognition,including CNS metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shen lin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>peking university, school of oncology, department of GI oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>zhang xiaodong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, school of oncology, department of GI oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhang xiaodong, MD</last_name>
    <phone>86-01-88196175</phone>
    <email>zxd0829@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhang xiaotian, MD</last_name>
    <phone>86-01-88196561</phone>
    <email>zhangxtxx@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhang Xiaodong</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhang xiaodong, MD</last_name>
      <phone>86-10-88196175</phone>
      <email>zxd0829@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>zhang xiaodong</name_title>
    <organization>Peking University, School of Oncology, Department of GI oncology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

